Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 63Neoplasms 40Colorectal Neoplasms 30Uterine Cervical Neoplasms 29Carcinoma, Hepatocellular 23Stomach Neoplasms 19Prostatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 19Ovarian Neoplasms 16Lung Neoplasms 15Esophageal Neoplasms 13Multiple Myeloma 12Pancreatic Neoplasms 11Endometrial Neoplasms 10Urinary Bladder Neoplasms 9Rectal Neoplasms 9Motor Activity 9Colonic Neoplasms 9Recurrence 8Lymphoma, Follicular 8Melanoma 7Lymphoma 7Liver Neoplasms 7Carcinoma, Ovarian Epithelial 7Triple Negative Breast Neoplasms 6Sleep Initiation and Maintenance Disorders 6Sarcopenia 6Neuroendocrine Tumors 6Leukemia 6Hematologic Neoplasms 6

Interventions

tislelizumab 1Oxaliplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Mid-low Rectal Cancer × 1 year × Clear all
NCT06333769 2025-08-15

Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

Fujian Cancer Hospital

Phase 2 Completed
38 enrolled
Gastrointestinal

Mid-low Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡